Serological levels of IGF-1 and IGFBP-3 in patients with Barrett's esophagus and esophageal adenocarcinoma: Longitudinal study

Background: Barrett's esophagus (BE) is an entity with a known histological progression to malig-nancy. The insulin-like growth factor (IGF) system is involved in the carcinogenesis through obesity-related mechanisms that include IGF and it has been associated with several types of cancer. Objectives: To evaluate the serological levels of IGF-1 and IGFBP-3 in patients with BE and esophageal adenocarcinoma.Patients and methods: Prospective study of patients with BE and esophageal adenocarcinoma who underwent upper endoscopy between September 2012 and December 2015. A baseline determination of IGF-1 and IGFBP-3 was performed. We included a control group of patients without BE. Results: One hundred sixteen patients were included: 36 controls, 62 with BE (42 without dys-plasia and 20 with dysplasia) and 18 with adenocarcinoma. IGF-1 and IGF-1/IGFBP-3 molar ratio showed a progression to high levels in BE and adenocarcinoma than in controls (IGF-1: 135.55 +/- 66.07 ng/ml, 148.33 +/- 81.5 ng/ml, 108.19 +/- 46.69 ng/ml, respectively; P = .049) (molar ratio: 0.23 +/- 0.91, 0.29 +/- 0.11, 0.19 +/- 0.06, respectively; P = .001), without differences bet-ween the histological types of BE. Fifty-four out of the 65 patients with BE were followed up (median of 58.50 months, range 12-113) and 11 of them (20.4%) presented progression to low-grade dysplasia (n = 8) or high-grade dysplasia/adenocarcinoma (n = 3), without differences in the IGF system compared with patients without progression. Conclusions: Patients with BE and esophageal adenocarcinoma have changes in the IGF sys-tem although the serological levels of IGF-1 and IGFBP-3 do not correlate with histological progression of BE.(c) 2022 Elsevier Espana, S.L.U. All rights reserved.